ACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on Tuesday

Posted by Stanley Muller on Aug 3rd, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) is expected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect ACADIA Pharmaceuticals to announce earnings of $0.0580 per share and revenue of $295.5080 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The business had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.ACADIA Pharmaceuticals’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.11 EPS. On average, analysts expect ACADIA Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD opened at $25.87 on Monday. ACADIA Pharmaceuticals has a 12-month low of $19.69 and a 12-month high of $28.35. The firm has a market capitalization of $4.43 billion, a price-to-earnings ratio of 11.76, a P/E/G ratio of 17.94 and a beta of 0.81. The stock’s 50 day moving average price is $23.74 and its two-hundred day moving average price is $23.20.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ACAD. Citigroup boosted their target price on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Royal Bank Of Canada raised their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Stifel Nicolaus lifted their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a research report on Tuesday, July 21st. BMO Capital Markets lifted their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 21st. Finally, Bank of America reiterated a “buy” rating and issued a $14.50 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.31.

View Our Latest Stock Report on ACAD

Insider Buying and Selling

In other news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James Kihara sold 5,401 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the transaction, the insider owned 24,509 shares in the company, valued at approximately $519,100.62. This trade represents a 18.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 26.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ACAD. Meeder Asset Management Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter worth $26,000. Transamerica Financial Advisors LLC grew its stake in shares of ACADIA Pharmaceuticals by 304.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,005 shares in the last quarter. Federated Hermes Inc. increased its position in ACADIA Pharmaceuticals by 277.5% during the fourth quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 1,185 shares during the period. Smartleaf Asset Management LLC increased its position in ACADIA Pharmaceuticals by 51.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,596 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 884 shares during the period. Finally, iSAM Funds UK Ltd acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter worth about $93,000. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.